ArticleNPJ digital medicine2025
Digital twins enable stratification of persistent atrial fibrillation patients for ablation diminishing unnecessary heart damage.
Article in NPJ digital medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- The Hodgkin-Huxley-Katz Prize Lecture: Heart digital twins: A new paradigm in arrhythmia medicine.The Journal of physiology · 2026Article
- Transmural heterogeneity in 3D fibrosis distribution is associated with endo-epicardial electrical dyssynchrony in persistent atrial fibrillation.The Journal of physiology · 2026Article
- Applications of digital twin technology in cardiometabolic disease management: a scoping review.BMC medical informatics and decision making · 2026Article
- Towards mechanisms-driven strategy for persistent atrial fibrillation ablation: Leveraging digital twins.Journal of precision medicine (Amsterdam, Netherlands) · 2026Article
- Relationships between three-dimensional fibrosis distribution, atrial adiposity, and voltage abnormalities associated with persistent atrial fibrillation.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026Article
- Versatile hiPSC Models and Bioengineering Platforms for Investigation of Atrial Fibrosis and Fibrillation.Cells · 2026Review
- Automated generation of ablation lesion masks: a unison of electro and optic flow mapping for persistent AF virtual cohorts.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Pulmonary vein isolation (PVI), the standard-of-care for atrial fibrillation (AF), is effective even in some persistent AF (PsAF) patients despite atrial fibrosis proliferation, suggesting that PVI could not only be isolating triggers but diminishing arrhythmogenic substrates. Left atrial (LA) posterior wall isolation is the prevalent adjunctive strategy aiming to address PsAF arrhythmogenesis, however, its outcomes vary widely. To explore why current PsAF ablation treatments have limited success and under what circumstances each treatment is most effective, we utilized patient-specific heart digital twins of PsAF patients incorporating fibrosis distributions to virtually implement versions of PVI (individual ostial to wide antral) and posterior wall isolation. In most digital-twins (60%) PVI greatly decreased LA substrate arrhythmogenicity without the need of wider lesions or posterior wall isolation. Using digital-twin findings, a strategy was developed to stratify PsAF patients to an appropriate ablation option based on fibrosis features, thus potentially avoiding unnecessary heart damage.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.